CO2017008395A2 - Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol - Google Patents
Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterolInfo
- Publication number
- CO2017008395A2 CO2017008395A2 CONC2017/0008395A CO2017008395A CO2017008395A2 CO 2017008395 A2 CO2017008395 A2 CO 2017008395A2 CO 2017008395 A CO2017008395 A CO 2017008395A CO 2017008395 A2 CO2017008395 A2 CO 2017008395A2
- Authority
- CO
- Colombia
- Prior art keywords
- fluticasone propionate
- dry powder
- dose
- salmeterol xinafoate
- powder inhaler
- Prior art date
Links
- 229960000289 fluticasone propionate Drugs 0.000 title abstract 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title abstract 5
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005018 salmeterol xinafoate Drugs 0.000 title abstract 3
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105479P | 2015-01-20 | 2015-01-20 | |
| PCT/US2016/014072 WO2016118589A1 (en) | 2015-01-20 | 2016-01-20 | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017008395A2 true CO2017008395A2 (es) | 2018-01-05 |
Family
ID=55443303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0008395A CO2017008395A2 (es) | 2015-01-20 | 2017-08-17 | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9415008B2 (https=) |
| EP (1) | EP3247331A1 (https=) |
| JP (1) | JP2018503687A (https=) |
| KR (1) | KR20170103975A (https=) |
| CN (1) | CN107530357A (https=) |
| AR (1) | AR104771A1 (https=) |
| AU (2) | AU2016209363B2 (https=) |
| BR (1) | BR112017015353A2 (https=) |
| CA (1) | CA2974125A1 (https=) |
| CL (1) | CL2017001859A1 (https=) |
| CO (1) | CO2017008395A2 (https=) |
| EA (1) | EA201791632A1 (https=) |
| HK (1) | HK1245125A1 (https=) |
| IL (1) | IL253499A0 (https=) |
| MA (1) | MA41378A (https=) |
| MX (2) | MX383344B (https=) |
| PE (1) | PE20171258A1 (https=) |
| TW (1) | TW201628607A (https=) |
| WO (1) | WO2016118589A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX374870B (es) * | 2013-10-07 | 2025-03-06 | Teva Branded Pharmaceutical Products R&D Inc | Inhalador de polvo seco. |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| US11344685B2 (en) | 2016-11-18 | 2022-05-31 | Norton (Waterford) Limited | Drug delivery device with electronics |
| CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN110064110A (zh) * | 2019-05-29 | 2019-07-30 | 上海理工大学 | 一种容积旋钮式干粉储存吸入装置 |
| GB2585206B (en) | 2019-07-01 | 2021-08-11 | Merxin Ltd | Portable inhaler |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| TWI224511B (en) | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | De-agglomerator for breath-actuated dry powder inhaler |
| TWI224512B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Reservoir pressure system for medicament inhaler |
| AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
| ES2474199T3 (es) * | 2000-11-30 | 2014-07-08 | Vectura Limited | Composiciones farmacéuticas para inhalaci�n |
| GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| US20040105821A1 (en) | 2002-09-30 | 2004-06-03 | Howard Bernstein | Sustained release pharmaceutical formulation for inhalation |
| US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| PL3111927T3 (pl) * | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| WO2011035128A1 (en) * | 2009-09-17 | 2011-03-24 | Mutual Pharmaceutical Company, Inc. | Method of treating asthma with antiviral agents |
| GB0919465D0 (en) | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| MX339742B (es) * | 2010-05-18 | 2016-06-07 | Teva Pharma Ireland | Contadores de dosis para inhaladores, inhaladores y flechas de los mismos. |
| EP2571486A4 (en) | 2010-05-20 | 2013-12-04 | Sun Pharma Advanced Res Co Ltd | DRY POWDER INHALATION COMPOSITION |
| KR20130140358A (ko) * | 2012-06-14 | 2013-12-24 | 한미약품 주식회사 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
| MX2015015150A (es) * | 2013-04-29 | 2016-02-18 | Sanofi Sa | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. |
| CA2910976C (en) * | 2013-05-03 | 2021-03-30 | Dow Global Technologies Llc | Process for equilibrium-limited reactions |
| MX374870B (es) | 2013-10-07 | 2025-03-06 | Teva Branded Pharmaceutical Products R&D Inc | Inhalador de polvo seco. |
| BR112017007587A2 (pt) * | 2014-10-16 | 2018-01-30 | Teva Branded Pharmaceutical Products R&D Inc | processo para preparar uma formulação farmacêutica em pó seca e inalável |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2016
- 2016-01-19 MA MA041378A patent/MA41378A/fr unknown
- 2016-01-20 EP EP16706919.4A patent/EP3247331A1/en not_active Withdrawn
- 2016-01-20 KR KR1020177023075A patent/KR20170103975A/ko not_active Ceased
- 2016-01-20 MX MX2017009122A patent/MX383344B/es unknown
- 2016-01-20 PE PE2017001234A patent/PE20171258A1/es unknown
- 2016-01-20 AU AU2016209363A patent/AU2016209363B2/en active Active
- 2016-01-20 JP JP2017556791A patent/JP2018503687A/ja active Pending
- 2016-01-20 HK HK18104726.3A patent/HK1245125A1/zh unknown
- 2016-01-20 US US15/001,853 patent/US9415008B2/en active Active
- 2016-01-20 US US15/544,900 patent/US20180015035A1/en not_active Abandoned
- 2016-01-20 CA CA2974125A patent/CA2974125A1/en not_active Abandoned
- 2016-01-20 BR BR112017015353-0A patent/BR112017015353A2/en not_active Application Discontinuation
- 2016-01-20 AR ARP160100136A patent/AR104771A1/es active IP Right Grant
- 2016-01-20 EA EA201791632A patent/EA201791632A1/ru unknown
- 2016-01-20 TW TW105101637A patent/TW201628607A/zh unknown
- 2016-01-20 WO PCT/US2016/014072 patent/WO2016118589A1/en not_active Ceased
- 2016-01-20 CN CN201680011413.7A patent/CN107530357A/zh active Pending
-
2017
- 2017-07-12 MX MX2021006751A patent/MX2021006751A/es unknown
- 2017-07-16 IL IL253499A patent/IL253499A0/en unknown
- 2017-07-18 CL CL2017001859A patent/CL2017001859A1/es unknown
- 2017-08-17 CO CONC2017/0008395A patent/CO2017008395A2/es unknown
-
2021
- 2021-05-04 AU AU2021202784A patent/AU2021202784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201628607A (zh) | 2016-08-16 |
| CA2974125A1 (en) | 2016-07-28 |
| PE20171258A1 (es) | 2017-08-28 |
| IL253499A0 (en) | 2017-09-28 |
| US20160206559A1 (en) | 2016-07-21 |
| AR104771A1 (es) | 2017-08-16 |
| WO2016118589A1 (en) | 2016-07-28 |
| US20180015035A1 (en) | 2018-01-18 |
| MX2021006751A (es) | 2021-07-15 |
| US9415008B2 (en) | 2016-08-16 |
| AU2021202784A1 (en) | 2021-05-27 |
| JP2018503687A (ja) | 2018-02-08 |
| AU2016209363B2 (en) | 2021-02-04 |
| MX2017009122A (es) | 2017-10-12 |
| AU2016209363A1 (en) | 2017-08-24 |
| CL2017001859A1 (es) | 2018-04-06 |
| CN107530357A (zh) | 2018-01-02 |
| HK1245125A1 (zh) | 2018-08-24 |
| EP3247331A1 (en) | 2017-11-29 |
| KR20170103975A (ko) | 2017-09-13 |
| EA201791632A1 (ru) | 2017-12-29 |
| MA41378A (fr) | 2017-11-28 |
| MX383344B (es) | 2025-03-13 |
| BR112017015353A2 (en) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004316A (es) | Inhalador de polvo seco. | |
| CO2017008395A2 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX2015013355A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| BR112016002574A8 (pt) | composição de enzima digestiva, processo para a preparação da composição de enzima digestiva, e, método para o tratamento de um paciente adulto ou pediátrico com necessidade da composição de enzima digestiva | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| MX2022009231A (es) | Inhalador de polvo seco y metodo de uso. | |
| MX2017008486A (es) | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. | |
| MY204827A (en) | Semaglutide in medical therapy | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| BR112016015281A8 (pt) | uso de um filtro em linha intravenoso, e método para preparação de um conjunto de infusão | |
| AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina | |
| MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca | |
| TH173838A (th) | เครื่องพ่นละอองยาผงแห้ง | |
| AR098868A1 (es) | Composición farmacéutica en polvo seco para inhalación |